Holen Sie sich die Stockscreener-App
29.14
6.66%
1.82
Handel nachbörslich:
29.14
Schlusskurs vom Vortag:
$27.32
Offen:
$28.18
24-Stunden-Volumen:
476.36K
Relative Volume:
0.74
Marktkapitalisierung:
$1.74B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
2.5651
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
-2.77%
1M Leistung:
+9.14%
6M Leistung:
-50.63%
1J Leistung:
-11.70%
1-Tages-Spanne:
$28.18
$29.39
1-Wochen-Bereich:
$27.27
$30.02
52-Wochen-Spanne:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
29.14 | 1.74B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Trading (AGIO) With Integrated Risk Controls - news.stocktradersdaily.com
Agios to Present at the 2025 RBC Capital Markets Global Healthca - GuruFocus
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - The Manila Times
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages AGIO Shareholders to Contact the Firm - ACCESS Newswire
Alpha Thalassemia Market Trends, Growth Forecast & Treatment - openPR.com
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Scotiabank cuts Agios Pharma stock target to $71, keeps outperform rating - Investing.com UK
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times
Agios to Reveal Latest Rare Disease Therapeutic Advances at Major BofA Healthcare Conference - Stock Titan
Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
AGIO Receives Price Target Adjustment from Scotiabank | AGIO Sto - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) - Seeking Alpha
Agios (AGIO) Reports Lower Q1 Revenue as sNDA for Thalassemia Pr - GuruFocus
Agios Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals Shares Down After Q1 Net Loss Widens, Revenue Misses Estimates - marketscreener.com
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Earnings call transcript: Agios Pharm beats EPS expectations in Q1 2025 - Investing.com
Agios Q1 2025 slides: PYRUKYND sales dip QoQ, pipeline advances toward key catalysts - Investing.com
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals: Q1 Earnings Snapshot - MySA
Agios Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Loss of $-1.55, vs. FactSet Est of $-1.81 Loss - marketscreener.com
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - ADVFN
An Overview of Agios Pharmaceuticals's Earnings - Nasdaq
Long Term Trading Analysis for (AGIO) - news.stocktradersdaily.com
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for - MSN
BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating - marketscreener.com
Agios Pharmaceuticals (AGIO) Price Target Lowered by BofA but Buy Rating Maintained | AGIO Stock News - GuruFocus
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 | AGIO Stock News - GuruFocus
Agios Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Rare Disease Biotech Agios Sets Q1 2025 Earnings Call: Key Updates Expected May 1 - Stock Titan
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - The Manila Times
Anemia Market Set to Witness Significant Growth by 2032, Driven by Rising Awareness and Novel Oral Alternatives | DelveInsight - Barchart.com
Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com India
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com Australia
Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView
Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia
Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa
RBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO) - The Globe and Mail
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FOUSE JACQUALYN A | Director |
Apr 10 '25 |
Sale |
25.90 |
7,497 |
194,172 |
149,220 |
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):